PRGO

#2045
Perrigo Company plc Ordinary Shares
10.7 0 USD
+9574.50%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
10.60
10.72
Годовой диапазон
0.11
22.01
Дневное изменение
+9574.50%
Месячное изменение
-9.86%
6-месячное изменение
-22.41%
Годовое изменение
-50.28%
Предыдущее закрытие
0.1 1
Open
10.6 3
Low
10.6 0
High
10.7 2
Volume
145
Открыть полный график Full chart

Financials

Обзор Отчетность Статистика Дивиденды
Квартал Год
  • Market Capitalization 1.48 B
  • Employee 8 100
  • Founded N/A
  • CEO Murray S. Kessler
  • Website www.perrigo.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Производители лекарств — специализированные и дженерики
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-0.74
Коэффициент цена/денежный поток
0.32
Дивиденды на акцию
0.29
Дивидендная доходность, %
20.88

Perrigo Company plc Ordinary Shares

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.

Новости